Acolbifene/GnRH agonist/prasterone combination therapy - Endoceutics
Alternative Names: Femitra; GnRH agonist/prasterone/acolbifene - EndoceuticsLatest Information Update: 14 Oct 2021
At a glance
- Originator Endoceutics
- Class Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Dehydroepiandrosterone replacements; Gonadotropin releasing hormone stimulants; Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Endometriosis
Most Recent Events
- 14 Oct 2021 Discontinued - Phase-III for Endometriosis in Canada (PO) (Endoceutics pipeline, October 2021)
- 14 Oct 2021 Discontinued - Phase-III for Endometriosis in Canada (SC) (Endoceutics pipeline, October 2021)
- 23 Jan 2018 NDR (Batch#13) - Added ADS because the product is listed on Endoceutics' pipeline